Tesamorelin

GHRH analog

The GHRH analog with an actual FDA approval, and the only one with solid trial evidence for reducing visceral fat.

Evidence strength: Moderate evidence. Real human data exists, with meaningful limitations. The visceral fat evidence is the strongest of any GHRH analog: multiple randomized placebo-controlled trials showed roughly 15 to 18 percent reductions in visceral adipose tissue measured by CT. The important qualifiers are that this was studied in a specific population, that the effect reverses when treatment stops, and that evidence for use in healthy adults seeking body composition change is extrapolation rather than data.

What it is

Tesamorelin is a stabilized GHRH analog approved by the FDA in 2010 for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. That approval matters here for a specific reason: it means the visceral fat effect was demonstrated in large randomized trials with imaging endpoints, not inferred from mechanism. Interest in it beyond that population follows from those results.

What people use it for

Visceral abdominal fat — the metabolically dangerous kind around the organs
Its approved indication in HIV-associated lipodystrophy
Growth hormone axis support in aging, off-label
Research interest in cognitive effects and liver fat

How it works

Same basic idea as sermorelin — prompt the pituitary rather than inject the hormone — but structurally modified to resist breakdown, so it lasts longer and produces a more sustained elevation in growth hormone and IGF-1. Growth hormone happens to be unusually effective at mobilizing visceral fat specifically, which is why the trial results landed where they did.

The technical version

Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoyl group attached to the N-terminus, conferring resistance to dipeptidyl peptidase-4 degradation and extending activity relative to native GHRH or sermorelin. It binds pituitary GHRH receptors, stimulating pulsatile endogenous GH release and raising IGF-1. Growth hormone promotes lipolysis preferentially in visceral adipose tissue, which expresses higher densities of GH receptors than subcutaneous fat.

What to realistically expect

The trial data measured visceral fat by CT at 26 and 52 weeks. This is a months-long intervention, and — importantly — the effect reverses on discontinuation. It is a treatment rather than a cure, which is worth understanding before starting.

What it will not do

Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.

It will not selectively remove subcutaneous fat. The effect is specific to visceral fat, which is not the fat most people are looking at in the mirror.
It will not maintain the result after you stop. Trials showed reaccumulation on discontinuation.
It will not substitute for the interventions that reduce visceral fat without a prescription — caloric deficit, resistance training, alcohol reduction, and sleep.
It has no efficacy data in healthy adults seeking body recomposition; that use is extrapolated from a different population.

Safety and who should be cautious

Because it went through full clinical development, the safety data is substantially better than most of this category. Injection site reactions are common. It raises IGF-1, which is why it is contraindicated in active malignancy and requires monitoring. It can worsen glucose tolerance, making it a real consideration in anyone with diabetes or prediabetes. Fluid retention and joint discomfort occur. Prohibited in sport. Not appropriate during pregnancy or breastfeeding.

Sourcing and quality

An FDA-approved product exists (Egrifta), and compounded versions are widely available. The price difference is large and the supply chains are not equivalent — worth deciding deliberately rather than by default.

Questions worth asking your provider

Should we image or measure my visceral fat so we know the starting point and whether it changed?
Given my glucose control, is a GH-raising compound appropriate for me?
What is the plan for when I stop, given the effect reverses?

Frequently asked questions

Is tesamorelin FDA approved?

Yes, for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. Other uses are off-label.

Does it work for general weight loss?

It was not studied for that. The demonstrated effect is on visceral fat specifically, in a specific population, and it reverses on discontinuation.

How is it different from sermorelin?

Both stimulate your own growth hormone. Tesamorelin is longer-acting, has an FDA approval and real trial evidence behind it, and costs considerably more.

Have questions about your own situation?

General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.

Request a Consultation

Sermorelin Aod 9604 Mots C

Educational disclaimer. This page is for general education and is not medical advice. It does not diagnose, treat, or recommend any substance. Many peptides are not FDA-approved; legal status varies and some are prohibited in sport. Discuss any decision with a licensed provider.